LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

24.66 0.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.4

Max

24.98

Põhinäitajad
By Trading Economics
Sissetulek	258M 216M
Müük	280M 459M
P/E Sektori keskmine	70.171 76.798
Aktsiakasum	1.67
Kasumimarginaal	47.04
Töötajad	705
EBITDA	258M 228M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+57.57% upside

Turustatistika
By TradingEconomics
Turukapital	-653M 3.1B
Eelmine avamishind	23.8
Eelmine sulgemishind	24.66

Uudiste sentiment

By Acuity

29%

71%

79 / 374 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. dets 2025, 16:47 UTC

Suurimad hinnamuutused turgudel

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. dets 2025, 16:10 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19. dets 2025, 22:33 UTC

Tulu

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. dets 2025, 22:19 UTC

Tulu

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. dets 2025, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 21:44 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 21:38 UTC

Tulu

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. dets 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. dets 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. dets 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. dets 2025, 18:00 UTC

Market Talk

Tulu

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. dets 2025, 17:41 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 17:24 UTC

Market Talk

Tulu

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. dets 2025, 16:29 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. dets 2025, 16:20 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. dets 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. dets 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. dets 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. dets 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 16:04 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. dets 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. dets 2025, 15:09 UTC

Tulu

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

57.57% tõus

12 kuu keskmine prognoos

Keskmine 38.84 USD 57.57%

Kõrge 117.8 USD

Madal 18 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

79 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.